Presentation Highlights the Efficacy of the Lead Aganocide Compound as a Potential Break-Through Treatment for Prevention of Urinary Catheter Blockage and Encrustation (UCBE) Often Leading to ...
EMERYVILLE, Calif., March 2, 2011 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company developing its first-in-class, anti-infective Aganocide ® ...
Citric acid 6.602g, glucono-delta-lactone 198mg, magnesium carbonate 3.177g; per 100mL; irrigation soln (pH 3.85). Dissolution of renal or bladder calculi composed of apatite or struvite in select ...
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay ® Pharmaceuticals, Inc. (NYSE MKT: NBY), a clinical-stage biopharmaceutical company developing non-antibiotic, topical antimicrobial products, today ...
NovaBay Pharmaceuticals, Inc., an advanced clinical-stage biopharmaceutical company developing anti-microbial products, today announced positive top-line results from its recently completed Phase 2 ...
Thirty-six patients with unsatisfactory treatment of neurogenic bowel dysfunctions (NBD) were enrolled from Spinal Units and Rehabilitation Centers in Italy. Treatment was for 3 weeks using a newly ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio A remotely operated magnetic-tipped ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results